Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Myeloid cells contribute to blood-retinal barrier breakdown in retinal ischemia-reperfusion injury
Author Affiliations & Notes
  • Lingli Zhou
    Wilmer Eye Institute, Johns Hopkins Medicine, Baltimore, Maryland, United States
  • Zhenhua Xu
    Wilmer Eye Institute, Johns Hopkins Medicine, Baltimore, Maryland, United States
  • Haining Lu
    Wilmer Eye Institute, Johns Hopkins Medicine, Baltimore, Maryland, United States
  • Yangyiran Xie
    Wilmer Eye Institute, Johns Hopkins Medicine, Baltimore, Maryland, United States
  • Grace Lee
    Wilmer Eye Institute, Johns Hopkins Medicine, Baltimore, Maryland, United States
  • Elia J Duh
    Wilmer Eye Institute, Johns Hopkins Medicine, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Lingli Zhou None; Zhenhua Xu None; Haining Lu None; Yangyiran Xie None; Grace Lee None; Elia Duh None
  • Footnotes
    Support  NIH EY022683; the Altsheler Durell Foundation, P30-EY001765 (Wilmer Core), RPB Unrestricted Grant (Wilmer Eye Institute, The Johns Hopkins University)
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 276. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lingli Zhou, Zhenhua Xu, Haining Lu, Yangyiran Xie, Grace Lee, Elia J Duh; Myeloid cells contribute to blood-retinal barrier breakdown in retinal ischemia-reperfusion injury. Invest. Ophthalmol. Vis. Sci. 2024;65(7):276.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Myeloid cells including microglia and macrophages are the major immune cells contributing to retinal disease. The objective of this study was to investigate the activation of myeloid cells after retinal ischemia-reperfusion injury (I/R) and to determine the effect of myeloid cell depletion on blood-retinal barrier breakdown induced by retinal I/R.

Methods : To induce the retinal ischemia-reperfusion injury, 8-10 week-old C57BL/6J mice were anesthetized with a cocktail of ketamine, xylazine, and acepromazine. The anterior chamber of one eye was cannulated with a 30-gauge needle attached to a line infused with sterile saline. The intraocular pressure was raised to 110 mmHg by elevating the saline reservoir for 90 mins. Inflammatory cell populations were evaluated with flow cytometry at 3 days after I/R injury. To deplete the myeloid cells in the retina, C56BL/6J mice received the CSF1R inhibitor PLX5622 in their diet for one week before I/R injury. Inflammatory gene expression was evaluated one day after I/R injury. Inflammatory cell population and leukocytosis were examined three days after I/R injury. To evaluate the effect of myeloid cell depletion on blood-retinal barrier breakdown in the I/R injury model, leakage of H3-mannitol tracer was measured in the retina after 1 hour of circulation.

Results : There was a significant increase in cell number and activation of myeloid cells in I/R retinas three days after injury compared with control retinas (n=9; p=0.014). PLX5622 treatment significantly reduced myeloid cell numbers in I/R retinas (n=; p<0.0001). There was a significant reduction in the expression of retinal inflammatory cytokines including as Il-1b, Tnf-a, and Il6, and chemokines including Ccl2, Cxcl2, and Cxcl10 one day after I/R injury in the PLX5622-treated mice. PLX5622 treatment significantly reduced retinal vascular leakage induced by I/R injury (n=10; p=0.01).

Conclusions : Myeloid cell proliferation and activation were observed at an early stage following retinal ischemia/reperfusion injury. Depletion of myeloid cells with PLX5622 ameliorated inflammatory cytokine and chemokine expression and blood-retinal barrier breakdown induced by I/R injury. These results indicate an important role for myeloid cells in regulation of retinal inflammation and blood-retinal barrier breakdown.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×